+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ninlaro

  • ID: 4775166
  • Report
  • 20 pages
  • Datamonitor Healthcare
1 of 2
Drug Overview
Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.

Preclinical studies suggest that Ninlaro demonstrates a stronger anti-tumor effect than Velcade (bortezomib; Takeda/Johnson & Johnson).
Note: Product cover images may vary from those shown
2 of 2
OVERVIEW
Drug Overview
Product Profiles
Ninlaro : Multiple myeloma

LIST OF FIGURES
Figure 1: Ninlaro for multiple myeloma – SWOT analysis
Figure 2: The authors drug assessment summary of Ninlaro for multiple myeloma
Figure 3: The authors drug assessment summary of Ninlaro for multiple myeloma
Figure 4: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
Table 1: Ninlaro drug profile
Table 2: Ninlaro pivotal trial data in multiple myeloma
Table 3: Ninlaro ongoing late-phase clinical trials in multiple myeloma
Table 4: Ninlaro sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 5: Patients treated with Ninlaro across the US, Japan, and five major EU markets, by country, 2017–26
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll